Red Havas has announced the launch of Red Havas Health, a global micro-network focused on health, in response to increasing demand from clients globally.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh